3-(6-Hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Catalog No. :
ACEPLQ067
CAS No. :
1416990-09-4
Molecular Formula :
C13H12N2O4
Molecular Weight :
260.25

IUPAC Name:3-(6-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione

3-(6-Hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$63.00Login to see priceIn stockInquiry
250mg98%$102.00Login to see priceIn stockIn stock
1g98%$233.00Login to see priceIn stockIn stock
5g98%$1163.00Login to see priceIn stockIn stock
25g98%$4628.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(6-Hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione
IUPAC Name3-(6-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione
MDL No.MFCD34407392
Molecular FormulaC13H12N2O4
Molecular Weight260.25
SMILESO=C(C(N(CC1=C2C=C(O)C=C1)C2=O)CC3)NC3=O
InChI KeyVOTVGZSDHZUGID-UHFFFAOYSA-N
Synonym3-(6-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione;2,6-Piperidinedione, 3-(1,3-dihydro-6-hydroxy-1-oxo-2H-isoindol-2-yl)-;3-(6-hydroxy-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
CAS No.1416990-09-4
PubChem CID71517903

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACEPLQ067 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACEPLQ067 route product structure diagram
    ACEPLQ0671416990-09-4 In Stock
Inquiry

2. ACEPLQ067 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACEPLQ067 route product structure diagram
    ACEPLQ0671416990-09-4 In Stock
Inquiry

Comments (0)